Half of estrogen receptor-positive breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy resistant and exhibit increased cancer stem cell (CSC) properties. We and others have demonstrated that progesterone (P4) increases CK5+ breast cancer cells. We previously discovered that retinoids block P4 induction of CK5+ cells. Here we investigated the mechanisms by which progesterone receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity. After P4 treatment, sorted CK5+ compared to CK5 − cells were more tumorigenic in vivo. In vitro, P4-treated breast cancer cells formed larger mammospheres and silencing of CK5 using small hairpin RNA abolished this P4-dependent increase in mammosphere size. Retinoic acid (RA) treatment blocked the P4 increase in CK5+ cells and prevented the P4 increase in mammosphere size. Dual small interfering RNA (siRNA) silencing of RARα and RARγ reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE). We confirmed by chromatin immunoprecipitation that P4 recruits PR to the CK5 promoter near the − 1.1 kb essential PRE, and also to a proximal region near − 130 bp that contains PRE halfsites and a RA response element (RARE). RA induced loss of PR binding only at the proximal site. Interestingly, RARα was recruited to the − 1.1 kb PRE and the − 130 bp PRE/RARE regions with P4, but not RA alone or RA plus P4. Treatment of breast cancer xenografts in vivo with the retinoid fenretinide reduced the accumulation of CK5+ cells during estrogen depletion. This reduction, together with the inhibition of CK5+ cell expansion through RAR/PR cross talk, may explain the efficacy of retinoids in prevention of some breast cancer recurrences.
INTRODUCTION
Greater than 70% of all breast cancers express estrogen receptor alpha (ER) at diagnosis and display various degrees of dependency on estrogens for proliferation. 1 While ER-targeted endocrine therapies have greatly improved survival for patients with ER+ disease, intrinsic or acquired resistance still accounts for half of all breast cancer deaths. 2 Furthermore, recurrences can occur after an extended remission (45 years), suggesting cell populations in ER+ tumors can survive a prolonged dormancy. 3, 4 One possible explanation for this recurrence is the cancer stem cell (CSC) theory, which posits that tumors contain a small population of cells that exhibit characteristics of normal stem cells including drug resistance, quiescence and replicative immortality, allowing tumors to reform. 5 Of note is that breast cancer cells can acquire a CSC phenotype through signaling or therapeutic pressure and thus prevention of the CSC phenotype may be equally as important as targeting existing CSCs. 6, 7 Understanding how subpopulations of CSCs are regulated in ER+ breast cancers is thus paramount to developing new treatment strategies.
Progesterone receptors (PR) are co-expressed in the majority of ER+ breast cancers and signify initial positive response to endocrine therapy. 8 The role of PR itself is complex; it can exert autonomous proliferative signals or oppose the mitogenic effects of estrogens in a context-dependent manner. [9] [10] [11] [12] In particular, we and others have shown that progesterone (P4) increases a population of ER − , cytokeratin 5 (CK5)+ breast cancer cells. 13, 14 CK5 is expressed in ER − luminal progenitor cell populations of the normal human breast, which give rise to ER+PR+ luminal cells. 15 CK5+ compared with CK5 − breast cancer cells have enhanced mammosphere forming potential, and are chemo-and endocrine therapy resistant. [16] [17] [18] P4 expansion of CK5+ breast cancer cells involves upregulation of PR target transcription factors such as KLF4, STAT5a and BCL6. [19] [20] [21] Additionally, endocrine therapy agents such as tamoxifen (Tam), fulvestrant (ICI) or estrogen depletion increase CK5 expression in breast cancer cell lines, and neoadjuvant Tam plus aromatase inhibitor treatment enriches for CK5+ cells in patient biopsy samples. 17 Factors that repress CK5+ cells in breast cancer are lesser known.
Via a small molecule screen we previously discovered that several retinoids including all-trans retinoic acid (ATRA) and two synthetic retinoids prevent P4 production of CK5+ breast cancer cells. 22 Retinoids (for example, ATRA, 9-cis RA, 13-cis RA) are ligands for nuclear receptors in the retinoid receptor subclass, which includes three retinoic acid (RA) receptors (RARα, -β and -γ) and three retinoid X receptors (RXRα, -β and -γ). These receptors form RAR/RXR heterodimers that can occupy DNA in the absence of ligand and often repress transcription; upon ligand binding they positively or negatively modulate gene transcription to regulate important cellular processes such as differentiation and cell death. 23, 24 This has led to successful use of ATRA in acute promyelocytic leukemia as a differentiating agent. 25 Retinoids are potently antiproliferative in breast cancer cells. 26 Treatment studies in breast cancer patients, however, have been mostly disappointing, with use of retinoids in combination treatment with Tam or chemotherapy failing to achieve study end points (reviewed in Garattini et al. 27 ). One exception is the synthetic retinoid fenretinide (Fen, 4-HPR), which has had some efficacy in prevention of premenopausal breast cancer. 28 Understanding the interplay between RARs and steroid receptors is important in determining contexts under which they could be therapeutically useful in breast cancer. RARα is positively regulated by estrogens in breast cancer cells, 29 and is co-localized at many ER DNA binding sites, where it either acts as a cofactor for ER modulation of gene transcription, 30 or competes with ER at promoter binding sites to antagonize gene transcription. 31 ATRA reduces PR messenger RNA (mRNA) and protein in breast cancer cells and attenuates activity of a progestin-responsive promoterreporter.
32,33
Here we investigated the molecular mechanisms by which P4 and RA through their cognate receptors regulate expression of CK5 and how this contributes to cancer cell stemness. We demonstrate that P4 induction of large mammospheres is dependent on CK5 expression, and that RA through RARs blocks both P4-mediated CK5 expression and mammosphere size. Furthermore, we identified two regions in the CK5 promoter that are essential for PR/RAR regulation, and describe a mechanism by which RARα selectively controls coactivator recruitment. Finally, we show in vivo that co-treatment with retinoids can prevent the enrichment of CK5+ cells seen during estrogen depletion. Therefore, retooling the use of retinoids to specific cases and timelines may revitalize their usefulness, specifically in conjunction with hormone therapies to abrogate P4 expansion of stem cells, or in some ER − CK5+ breast cancers where retinoids may prevent breast cancer recurrence.
RESULTS

P4-expanded CK5+ breast cancer cells are tumorigenic
We have previously demonstrated that CD44+ breast cancer cells that are enriched in CK5 expression are more tumor-initiating. 13 Furthermore, breast cancer cell lines with larger P4-dependent CK5+ populations following suppression of microRNAs (miR)29 and miR141 had increased tumor-initiating ability. 19, 20 To validate these observations and more directly measure CK5 involvement in tumorigenicity, we used a system in which T47D breast cancer cells are integrated with a CK5 promoter-GFP reporter. 16 Cells were treated for 24 h with P4 in vitro to induce a CK5+ cell population, then CK5+ and CK5 − cells were isolated by fluorescence-activated cell sorting (Supplementary Figure 1a) . Female nude mice supplemented with estrogen slow release pellets were bilaterally injected with sorted CK5+ and CK5 − cells subcutaneously in opposing fourth mammary fat pads at dilutions ranging from 10 2 to 10 5 . Tumors were palpated through 6 weeks post injection (Supplementary Figure 1b) . Limiting dilution analyses revealed that CK5+ cells initiated tumors more efficiently than CK5− cells (Table 1) . These data provide additional confirmation that CK5+ breast cancer cells have enhanced tumor initiation ability.
CK5 is necessary for P4-mediated increase in breast cancer cell mammosphere size P4 increases the mammosphere forming potential of breast cancer cells. 20, 21 To test whether CK5 is necessary for the P4 effect on mammospheres, we utilized small hairpin RNA (shRNA) inhibition coupled with an adapted in vitro mammosphere assay compatible with automated quantitation. T47D cells constitutively expressing ZsGreen were transduced with three different lentiviral-packaged shRNAs to CK5, resulting in two cell lines with impaired P4 induction of CK5 (Figure 1a ). Cell lines transduced with two independent shRNAs (#22 or #78) targeting CK5 or a non-targeting control (shCont) were seeded into mammosphere media with vehicle or P4, and sphere number and size were assessed after 2 weeks (Figure 1b) . P4 consistently increased average mammosphere size by 1.6-fold in shCont cells; this increase was attenuated in both shCK5 lines (Figure 1c) . A significant difference in the number of mammospheres was also observed in P4 compared to vehicle-treated control cells, albeit only with large mammospheres (44500 μm 2 ) (Supplementary Figure 2) . We thus used mammosphere size as our primary metric for this study. We conclude that CK5 is necessary for P4 to produce large mammospheres.
Retinoids block P4-enhanced CK5 expression and mammosphere size To validate our previous work that identified retinoids as potent inhibitors of P4-dependent induction of CK5, 22, 34 we measured CK5 mRNA levels in response to vehicle, P4, 9-cis RA or P4 plus RA in three breast cancer cell lines (T47D, MCF7, BT-474). MCF7 and BT-474 cells were pretreated with 17β-estradiol (E2) for 48 h to induce PR levels. P4 significantly increased CK5 mRNA levels in all three cell lines while RA alone had no effect on CK5 mRNA levels in T47D and BT-474 cells, but significantly decreased CK5 mRNA in MCF7 cells. RA significantly attenuated the P4-mediated increase in CK5 transcripts in all three cell lines (Figure 2a ). CK5 protein expression was directly assessed in T47D cells by immunocytochemistry (ICC) and immunoblot. By ICC, P4 increased the population of CK5+ cells to 5.2% compared to vehicle (0%), One animal was killed for health reasons prior to week 6, and was excluded from the analysis. Data were analyzed using ELDA software. 58 whereas co-treatment with RA blocked this increase (Figure 2b) . Similarly, the P4-mediated increase in CK5 protein was blocked by RA as measured by immunoblot (Figure 2c ). We compared a doseresponse of RA (1 nM-1 μM) plus or minus P4 and determined via immunoblot that 100 nM was the most effective lowest concentration, and chose that dose for remaining studies (Supplementary Figure 3a) . Thus, RA effectively blocks the P4-mediated increase in CK5 expression primarily through a reduction in CK5 mRNA transcripts.
We assessed PR and RARα expression and co-localization in T47D cells under four different hormone conditions. By immunoblot PR (both PRA and PRB isoforms) protein decreased with RA treatment, but to a lesser extent than with P4-mediated downregulation ( Figure 2c ). RARα was present in T47D cells and its levels were unaffected by any treatments (Figure 2c ). By dual ICC, PR and RARα were frequently co-localized in the nucleus of T47D cells, with occasional solely PR+ and RARα+, or double-negative cells ( Figure 2e ). No differences in co-localization were observed under the different hormone conditions. Thus, PR levels decrease slightly with RA treatment but RARα was not affected by P4 treatment.
Since CK5 was required for the P4-mediated increase in mammosphere size, we next assessed if RA inhibition would also impede this process. T47D cells treated with vehicle, P4, RA or P4 plus RA were assessed for mammosphere formation (Figure 2d ). Indeed, RA reduced baseline mammosphere size (0.4-fold) and also prevented the P4-mediated increase (1.7-fold, reduced to 0.9-fold) in mammosphere size. Therefore, RA antagonizes the effects of P4 on CK5 transcription and CSC phenotype.
RARs are necessary for retinoid antagonism of P4-dependent increases in CK5 expression and mammosphere size We next determined if RA was acting through RARs to block P4-mediated induction of CK5. Luminal breast cancer cells mainly express RARα and RARγ. 35 Therefore, we used scrambled siRNA (siNT) or small interfering RNA (siRNA) targeting RARα (siRARα), RARγ (siRARγ), alone or simultaneously, in T47D cells stably expressing a CK5 promoter-driven luciferase reporter (Figure 3a ). Similar to non-targeting siRNA, when cells were transfected with either siRARα or siRARγ alone, RA still inhibited P4 induction of the CK5 promoter ( Figure 3b ). When both RARα and RARγ were depleted, however, RA was unable to attenuate P4 activation of the CK5 promoter, indicating that RA can act through either RAR isoform to block CK5 induction. Because 9-cis RA is a ligand for both RARs and RXRs, we next determined if the inhibition of CK5 required RARs using the selective RAR agonist TTNPB. In T47D cells, TTNPB blocked P4 induction of CK5 as efficiently as RA ( Figure 3c ). TTNPB also attenuated the P4 increase in mammosphere size similar to RA in MCF7 cells (Figure 3d ). TTNPB blocked P4 induction of CK5 at doses as low as 1 nM (Supplementary Figure 3b) . These data indicate that agonist-bound RARα or RARγ, presumably through dimerization with RXRs, is sufficient to mediate repression of P4-induced CK5 expression and mammosphere size.
PR regulates CK5 transcription through direct binding to the proximal promoter We next investigated the mechanism by which PR increases transcription of the CK5 gene. To narrow down the region(s) of the CK5 promoter required for PR responsiveness, we constructed a series of 5' and internal deletion mutants using a 6 kb region of the human proximal CK5 promoter upstream of luciferase in a lentiviral vector (Figure 4a ). Constructs were stably integrated into T47D cells and P4 responsiveness was tested. P4-induced luciferase activity was significantly decreased in four constructs with deletions incorporating a region 1.1 kb upstream of the transcriptional start site (TSS). This region contains a sequence (GGAACAGGGTGGTTC, − 1098 bp from the TSS) with extensive identity to an optimal progesterone response element (PRE) identified by mutagenesis studies 36 and coincides with the location of a PR binding site upstream of the CK5 TSS identified by genome-wide analysis of PR DNA binding in T47D cells. 37 To confirm that PR was binding at this PRE, we performed chromatin immunoprecipitation (ChIP) for PR followed by quantitative PCR using two independent sets of primers surrounding this region. Indeed, there was significant enrichment of PR bound to the − 1.1 kb PRE region in P4 compared to vehicle-treated T47D cells Figure 4) . To determine if RA could preclude ligand-activated PR from binding to the − 1.1 kb PRE, we pretreated cells with RA for 30 min followed by P4 treatment. RA did not prevent PR from binding to the − 1.1 kb PRE (Figure 4b ), excluding loss of PR DNA binding at this site as a mechanism of RA antagonism of PR-mediated CK5 transcription.
RARα and coactivators are recruited to response elements in the CK5 promoter with P4 but not P4 plus RA treatment Previous studies in keratinocytes identified that RARα binds to the CK5 promoter~130 bp upstream of the TSS at what was termed a negative RA response element. 38, 39 We speculated a similar mechanism could occur in breast cancer cells. We therefore treated breast cancer cells with vehicle, P4, RA or RA plus P4 and performed ChIP for RARα followed by quantitative PCR with primers surrounding the negative RARE. Interestingly, RARα was only present at the negative RARE with P4 treatment, and was absent with RA alone or RA plus P4 (Figure 5b ). We therefore tested RARα recruitment to the − 1.1 kb PRE under the same conditions, and similarly found that RARα was associated with the PRE region only under P4 conditions, but not with either RA alone or RA plus P4 (Figure 5c ). Furthermore, P4 treatment induced PR recruitment at the − 130 bp region, which also contains PRE halfsites, 40 but RA blocked this recruitment (Figure 5d ). To investigate the activation state of the CK5 promoter, we performed ChIP for coactivators p300 and CBP. p300 was present at both the proximal and distal promoter sites in a P4-dependent manner, but was absent with co-treatment of P4 plus RA. CBP was also recruited in a P4-dependent manner to both promoter sites, but with less efficiency with co-treatment with P4 plus RA. These data suggest that the proximal binding region, while not sufficient for transcription itself, acts as a sensor for positive or negative enhancement through RARs. Figure 5f depicts a schematic of how P4 produces a functional coactivator bridge between PR occupied distal and RARα occupied proximal enhancers, whereas RA treatment disrupts this bridge by removal of RARα/p300.
Co-treatment with retinoids reduces accumulation of therapy resistant CK5+ cells during endocrine therapy Breast cancer cells treated with ER-targeted endocrine therapies show a gradual increase in the number of CK5+ cells. 17 We reasoned that co-treatment with retinoids may reduce the number of CK5+ cells that accumulate, and thus could prevent recurrences by lessening residual tumor-initiating cells. To test this, we injected female NSG mice with T47D cells supplemented with E2 and allowed tumors to establish to 75 mm 3 . Tumors were then stratified into four groups: continued on E2 plus vehicle or the synthetic retinoid fenretinide (Fen; 100 mg/kg) or estrogen withdrawal (EWD) plus vehicle or Fen; treatments lasted for 3 weeks. The EWD groups trended toward a decrease in tumor growth compared to E2 alone, achieving significance at the study end point for the EWD only (Figure 6a) . EWD tumors showed a robust increase in CK5+ cells compared to E2-treated tumors, while Fen prevented this increase during EWD (Figure 6b and c) . Therefore, retinoids can decrease the Figure 3 . RARs are required for RA inhibition of P4-induced CK5 expression and P4 production of large mammospheres. (a) T47D cells stably expressing a CK5 promoter-driven luciferase reporter were transfected with non-targeting siRNA (siNT), or siRNA to RARα or RARγ for 24 h, then treated with either ethanol vehicle or 100 nM P4 for an additional 24 h. Lysates were collected and analyzed by immunoblot. Relative RARα or RARγ levels are normalized to α-tubulin loading control and indicated relative to the vehicle treated siNT. (b) T47D cells were transfected as above and treated with vehicle, 100 nM P4, 100 nM 9-cis RA or both P4 plus RA. Lysates were collected and luciferase assays performed. Luciferase was graphed as fold change over vehicle control for each group of siRNAs. Experiments were performed three times. Data represent mean ± s.e.m. The four treatments were compared via analysis of variance (ANOVA)/Tukey within each of the siRNA groups, *Po 0.05, **Po0.01, ***Po0.001. (c) T47D cells were treated with vehicle or P4 as above with the addition of two groups, 10 nM of the RAR selective agonist TTNPB minus or plus P4. CK5 and PR (PRA and PRB isoforms) expression were measured by immunoblot. (d) MCF7 cells stably expressing ZsGreen were plated at a density of 100 cells per well in quintuplicate in mammosphere media in 96-well plates and treated with 10 nM E2 (to induce PR levels) plus the following hormone combinations: ethanol vehicle, 100 nM P4, 100 nM 9-cis RA, P4 plus RA, 10 nM TTNPB or P4 plus TTNPB. After 2 weeks, mammospheres were analyzed using the IncuCyte Zoom. Data represent mean mammosphere size ± s.e.m. All groups were compared via ANOVA/Tukey, *P o0.05, **P o0.01, ***P o0.001. NS, not significant. accumulation of CK5+ cells associated with prolonged endocrine treatment.
DISCUSSION
CKs are intermediate filament proteins that form tetrameric complexes of two Type I and two Type II peptides important for cell structure and motility. 41 However, CKs can influence other cellular processes such as proliferation, migration, invasion and stress-related signaling. [42] [43] [44] [45] For example, CK17 interaction with the scaffolding protein 14-3-3σ in keratinocytes facilitates its translocation to the cytoplasm to activate Akt signaling and cell cycle progression. 43 Similarly, 14-3-3σ interacts with CK5, CK17 and actin in basal-like breast cancer cells to facilitate cell migration and invasion. 46 CK14 and CK5 are found in cells at the leading edge of breast cancer invadopodia, 46 ,47 suggesting they are important for cancer cell invasion. Thus, CKs can influence a wide variety of processes important for cancer cells. CK5 is a poor prognostic marker in both basal-like and luminal-like breast cancer.
14, 48 Here we show that CK5+ cells (induced by P4 treatment) have high tumorigenic potential and that CK5 is necessary for the P4-mediated increase in mammosphere size. P4 is a key hormone promoting expansion of murine mammary stem cells and human breast progenitor cells, [49] [50] [51] an action that is maintained in some breast cancers. 13, 14, 16 On the contrary, RA promotes stem cell differentiation and inhibits expression of CK5 in the skin. 38, 52 Therefore, a balance of PR-RAR regulation of CK5 may be pivotal in dictating a breast CSC phenotype. Figure 4 . PR is recruited to the CK5 promoter near a PRE that is necessary for P4 transcriptional activation. (a) P4 action requires a region containing a putative PRE 1098 bp upstream of the TSS. Deletion constructs were engineered from a 6 kb fragment of the CK5 promoter upstream of luciferase in a lentiviral vector using existing restriction sites. The left side of the graph indicates relative size of the promoter construct with 5' or internal deletions, and the location of putative PRE half-sites, or full majority consensus sequence based on that reported by Lieberman et al. 36 and Graham et al. 37 Constructs were transduced into T47D cells and stable puromycin resistant pools selected. Cells were then seeded at 5000 cells per well in 96-well plates and treated with vehicle or 100 nM P4 for 24 h. Lysates were collected and luciferase activity analyzed using the Luciferase Assay Kit (Promega). Relative fold changes are indicated for each construct over vehicle control. Experiments were repeated three times. Data represent mean ± s.e.m. Data were analyzed by analysis of variance (ANOVA)/Dunnett using the full-length 6 kb promoter construct as the control, **P o0.01, ***Po 0.001. (b) ChIP using an antibody for PR or IgG control in T47D cells that were treated with vehicle, 100 nM P4, 100 nM 9-cis-RA or P4 plus RA. Experiments were performed three times. Data represent mean (percent input) ± s.e.m. Primer set one values were compared via Student's t-test; for primer set two, each group (IgG or PR) was compared via ANOVA/ Tukey post hoc, **P o0.01, ***P o0.001. (c) Diagram showing location of primer sets used in b. NS, not significant.
In this paper we investigated the mechanism by which P4 and RA modulate expression of CK5 through their cognate receptors. Both PR and RARs are members of the nuclear receptor family of ligand-activated transcription factors; PRs belong to the steroid hormone receptor subclass, whereas RARs belong to the RXR heterodimer subclass. 53 Previous studies demonstrated progestins and RA cross regulate expression of each other's receptors in breast cancer cells. RA decreased PR mRNA and protein levels, and conversely progestins decreased RARα and RARγ at the transcript level. 32, 33, 54 We confirmed that RA decreases PR protein levels but did not observe the reverse within a 24 h window (Figure 2c) . Therefore, while RA could partially reduce progestin potency by lowering PR levels, we speculated other mechanisms likely contribute to this cross talk and investigated functional interactions between PR and RARs at the gene level.
Here we define unique convergence between RAR and PR signaling at the CK5 locus in breast cancer cells (Figure 5f ). We describe two core promoter regions that affect transcription: a more distal (−1.1 kb from the TSS) region containing a PRE and a proximal region centered at − 130 bp that contains a previously described RARE 38, 39 and glucocorticoid receptor half-sites. 40 The distal PRE region is essential for robust P4 activation of the gene (Figure 4a ), while the proximal region alone is not sufficient itself for activation. P4 recruited PR and essential coactivators (p300 and ) and (e) ChIP for PR, p300 and CBP was performed in T47D cells using primers for the two promoter regions as described in Figure 4b . nd, not detectable by qPCR. Experiments were repeated three times. Data represent mean (percent input) ± s.e.m. The four treatments within each group (IgG, RARα, PR, p300, CBP) were compared via analysis of variance/Tukey post hoc *Po 0.05, **Po 0.01, ***P o0.001. (f) Diagram of proposed coactivator bridging between enhancer elements. Under P4 conditions, PR and RARα occupy their respective response elements and coactivators form a functional bridge. RA removes RARα/p300 and reduces CPB occupancy, disrupting the bridge. CBP) to the promoter region when using primers for either the proximal or distal sites. However, we were surprised that P4 alone was sufficient to recruit RARα, and that RA alone did not induce RARα binding at the proximal − 130 bp/RARE region. In keratinocytes, RA induces RARα binding to negative RAREs of multiple basal CKs promoters including CK5 (-130 bp), CK6, CK14, and CK17, and prevents their expression, likely through recruitment of corepressors, to maintain differentiation. 38, 39 We conclude that RAR regulates CK5 in breast cancer cells through a different mechanism. We propose that coactivators form a bridge between two nuclear receptor-occupied CK5 promoter elements in breast cancer cells, and that RARα acts as a sensor for RA, which redirects RARα and p300 away to disrupt the bridge (Figure 5f ). Thus a reduction in RARs was not sufficient to decrease P4 transcription of CK5 suggests that RARα is not an essential positive cofactor, but is required for negative regulation through the proximal site. This proposal is intriguing in light of reports that describe widespread co-localization of RARα near ER binding sites in breast cancer cells; RARα therein acts as either as a positive cofactor or a negative regulator of ER gene transcription. 30, 31 We have found no evidence that either estrogens or ER directly affect CK5 transcription in breast cancer cells. The gradual increase in CK5+ cells in response to antiestrogen treatment 17 suggests that this occurs through indirect transcriptional mechanisms. Collectively, our data support that CK5 is an important target for hormonal and nuclear receptor regulation that affects the downstream phenotype of breast cancer cells.
Retinoids have been extensively explored clinically against breast cancer based on promising preclinical studies. 26 However, several trials using retinoids as single agents or in combination with Tam or chemotherapy for breast cancer failed to meet study objectives (reviewed in Garattini et al. 27 ). One exception is the synthetic retinoid-like compound fenretinide, which is effective in prevention of secondary breast cancer in young women. 28 Our unbiased screening results revealed that retinoids prevent the P4 expansion of CK5+ breast cancer cells. 22 RAs may therefore be more efficacious in preventing initial transforming events, or conversion to a CSC phenotype, but may be less effective in reverting existing CSCs. On the basis of our data, we suggest that under the right contexts retinoids may reduce the acquisition of cells prone to tumor recurrence, an issue of particular relevance to luminal breast cancer, which can have long dormancy periods prior to relapse. 4 In addition, the progestin-associated increase in breast cancer incidence during hormone replacement therapy is hypothesized to occur through expansion of stem cells; 55 RA cotreatment could prospectively prevent this.
Taken together, our work describes cross talk among nuclear receptors PR and RARs at a single gene that is tied to a breast CSC phenotype. However, we speculate this cross talk occurs at a broader genome level in breast cancer cells. An emerging paradigm in nuclear receptor research is co-occupancy of multiple nuclear receptors at regulatory sites and co-dependency for transcriptional activation, or conversely transrepression. 11, 12, 30 Further understanding of these complex relationships at the genome-wide level and in whole-tumor models may allow for better use of multiple-hormone treatments that target specific nuclear receptor relationships and co-dependencies to prevent or treat breast cancers.
MATERIALS AND METHODS
Cell culture and shRNA Breast cancer cell lines (T47D, MCF7, BT-474) were obtained from the University of Colorado Cancer Center Tissue Culture core. Cells were maintained in minimal Eagle's medium, 5% fetal bovine serum, 1 × NEAA, 1 × 10 − 9 M insulin, 0.1 mg/ml sodium pyruvate and 2 mM L-glutamine. Cell lines were authenticated using short tandem repeat analysis, and tested negative for mycoplasma using the MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). shRNAs targeting CK5 (TRCN0000425222, TRCN0000433559, TRCN0000083878) and a non-targeting clone (SHC0002) were purchased from Sigma Mission shRNA library (Functional Genomics facility, University of Colorado, Boulder, CO, USA). Cells were transduced with virus containing the shRNAs and stable pools selected with puromycin.
CK5 promoter deletion constructs
Constructs were created from the previously described 6 kb fragment of the human CK5 promoter cloned into a lentiviral vector upstream of firefly luciferase 16 using the restriction enzymes listed in Supplementary Table 1 . All constructs were analyzed via gel electrophoresis to verify size deletions and sequenced to confirm appropriate deletion. Cells were transduced with virus containing each construct and stable pools selected with puromycin.
Luciferase reporter assay and siRNA T47D cells stably expressing CK5 promoter-luciferase reporter constructs were grown in media containing charcoal stripped serum for 24 h. Cells were then transfected with DharmaFECT 1 (T-2001-02, Dharmacon, Lafayette, CO, USA) non-targeting siRNA (D-0081810-10), or 10 nM siRNA targeting RARα (L-003437-00, Dharmacon), RARγ (L-003439-00, Dharmacon) or both together for 24 h, followed by treatment with vehicle (EtOH) or P4 (100 nM) for an additional 24 h. Lysates were harvested and assayed using the Luciferase Assay System (Promega, Madison, WI, USA).
Chromatin immunoprecipitation assay
For ChIP experiments, T47D cells were grown to 70-80% confluency in 15 cm 2 dishes in phenol red-free media containing charcoal stripped serum. The next day, cells were pretreated for 30 min with 100 nM RA or vehicle then treated with 100 nM P4 or vehicle for 1 h. Immunoprecipitation for PR was performed using antibody PR Ab-8 (recognizes both PRA and PRB, MS-298-P, Thermo Fisher, Grand Island, NY, USA), RARα, p300, (ab41934, ab54984, Abcam, Cambridge, MA, USA) or CBP (7389, Cell Signaling, Danvers, MA, USA). Cells were processed using the ChIP-IT Express kit (Active Motif, Carlsbad, CA, USA). Chromatin was sheared using an S220 Focused Ultrasonicator (Covaris, Woburn, MA, USA).
Mammosphere formation assay
ZsGreen-labeled cells were plated at a density of 100 cells per well in 96-well ultra-low attachment plates in quintuplicate in 100 μl MammoCult Media (Stemcell Technologies, Vancouver, BC, Canada) containing 1% methylcellulose plus indicated treatments. Cells were grown for 2 weeks, fed with additional media without methylcellulose containing treatment once per week, then imaged and analyzed for sphere number and size using parameters on the FITC channel using the IncuCyte ZOOM Live Cell Analysis System (Essen Bioscience, Ann Arbor, MI, USA).
Immunoblotting
Whole-cell lysates were collected in RIPA buffer following indicated treatments. Proteins were immunoblotted with primary antibodies to CK5 (mouse NCL-L-CK5, Leica Biosystems, Buffalo Grove, IL, USA), RARα (sc551, Santa Cruz, Dallas, TX, USA; ab76074, Abcam), RARγ (sc550, Santa Cruz), alpha-tubulin (ST1568, Sigma, St Louis, MO, USA) or PR (PgR 1294, recognizes both PRA and PRB, Dako, Carpinteria, CA, USA) followed by IRDye 800CW Goat-Anti-Mouse IgG (926-32210, Li-Cor Biosciences, Lincoln, NE, USA) and IRDye 680LT Goat-Anti-Rabbit IgG (926-68021, Li-Cor Biosciences). The Odyssey Infrared Imaging System (Li-Cor Biosciences) was used to image immunoblots, and Image Studio Lite (Li-Cor Biosciences) was used for blot analysis.
Immunohistochemistry and Immunocytochemistry
Immunohistochemistry and ICC were performed essentially as previously described. 20, 56 Primary antibodies to CK5 (NCL-L-CK5, Leica Biosystems, 1:200), RARα (ab28767, Abcam, 1:100) and PR (PgR 1294, Dako, 1:500) were applied, followed by secondary antibodies, and developed using ImmPRESS Peroxidase detection kit (Vector Laboratories, Burlingame, CA, USA) for immunohistochemistry and secondary fluorescent antibodies (A11029, A11037, Invitrogen, Grand Island, NY, USA) for ICC. For immunohistochemistry, slides were scanned into the Aperio digital pathology system (Leica Biosystems) and whole sections analyzed for percent of positive cells using an algorithm tuned for CK5, therefore blinding was not necessary.
Quantitative reverse transcription PCR RNA was harvested using QIAzol lysis reagent (Qiagen, Venlo, the Netherlands), qRT-PCR was performed using Absolute Blue Sybr Green (Thermo Fisher). Analysis was performed using the Pfaffl method for quantitative PCR. 57 Primers targeting genomic DNA are as follows: − 1.1 kb primer set 1 (Fwd 5′-GAGTGGGTGTGGTTTAGAACAG-3′, Rev 5′-GTCTATGGATTGTCCTGCCAG-3′), − 1.1 kb primer set 2 (Fwd 5′-CTGGCAGGACAATCCATAGAC-3′, Rev 5′-CCAGCAAGCTCTATTCCACTAG-3′), − 130 bp primer set (Fwd 5′-CCAAGAGATCAGTGCTGCAAGG-3′, Rev 5′-GTTACCCAGGAACGGTGATGC-3′).
Limiting dilution analysis and tumor growth
Experiments involving animals were performed under an approved University of Colorado Institutional Animal Care and Use Committee protocol. For limiting dilution analysis, T47D cells harboring CK5 promoter-GFP were treated with 100 nM P4 for 24 h, GFP+ and GFP − cells collected by fluorescence-activated cell sorting, serially diluted into Cultrex (Trevigen, Gaithersburg, MD, USA) and an equal number of GFP+ and GFP − cells as indicated were injected bilaterally into opposing fourth mammary fat pads of 8-week-old female nu/nu mice (Jackson Labs, Bar Harbor, ME, USA). All animals were supplemented with silastic pellets containing 17β-estradiol (1 mg). Tumors were palpated twice weekly for 6 weeks. For treatment experiments, T47D xenografts were developed by injecting 1 × 10 6 T47D cells in Cultrex (Trevigen) bilaterally into the fourth mammary fat pads of 8-week-old female NOD/SCID mice (Jackson Labs) supplemented with silastic pellets containing 17β-estradiol (1 mg). When tumors reached an average of 75 mm 2 , mice were stratified into four treatment groups with equal average tumor volume (n = 5 animals each); continued on E2 or EWD, both plus/minus fenretinide. Tumors were measured 2x per week and volumes estimated by the formula l(w 2 )/2. Fenretinide (2.5 mg/mouse) or peanut oil vehicle was administered subcutaneously 2x per week; EWD was performed by surgical removal of the silastic estrogen pellet. After 3 weeks of treatment, mice were killed, and tumors collected and analyzed by immunohistochemistry. Sample number was calculated at 80% power and α = 0.05.
Statistical methods
Data are represented as mean ± s.e.m. unless otherwise noted, and analyzed using a two-tailed Student's t-test or one-way analysis of variance followed by either a Tukey or Dunnett multiple comparison post hoc test as indicated. Prism 6.0 (GraphPad Software, La Jolla, CA, USA) was used for statistical analyses when samples met variance and normality tests. Po0.05 were considered significant.
